10x Genomics (TXG) EBITDA (2018 - 2026)

10x Genomics has disclosed EBITDA across 9 years of filings, most recently posting -$17.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$17.0 million, up 56.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$38.7 million (up 77.55% YoY), and the FY2025 annual result was -$61.0 million, up 68.65% from the prior year.
• EBITDA came in at -$17.0 million for Q1 2026 at 10x Genomics, up from -$19.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $30.1 million in Q2 2025 to a low of -$94.8 million in Q3 2023.
• The 5-year median for EBITDA is -$41.7 million (2022), against an average of -$41.5 million.
• Across the five-year window, EBITDA plunged 471.61% in 2022 and surged 172.18% in 2025, its largest moves.
• 10x Genomics' EBITDA stood at -$23.1 million in 2022, then slumped by 138.95% to -$55.2 million in 2023, then increased by 9.69% to -$49.8 million in 2024, then soared by 60.79% to -$19.5 million in 2025, then advanced by 12.77% to -$17.0 million in 2026.
• The last three EBITDA figures came in at -$17.0 million (Q1 2026), -$19.5 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.